STOCK TITAN

MindWalk Holdings (HYFT) Stock Price, News & Analysis

HYFT NASDAQ

Ticker history: IPA became HYFT (MindWalk Holdings Corp.) on . Earlier news and filings retain their original names and dates. View IPA history.

Published by Stock Titan Data refreshed

Price Move History

Daily moves over 5%
78 252 sessions, November 18, 2025 to November 18, 2026
Largest daily move
+26.2% close of May 20, 2026
1-year change
-48.9% closing prices, November 18, 2025 to November 18, 2026
1-month change
-31.3% closing prices, October 16, 2026 to November 18, 2026

Company Description

MindWalk Holdings Corp. (NASDAQ: HYFT) is a Bio-Native AI company in the healthcare and biotechnology sector that focuses on transforming drug discovery and development. The company describes itself as operating at the intersection of TechBio and next-generation drug discovery, combining artificial intelligence, multi-omics data, and advanced laboratory research to accelerate the discovery and development of biologics.

MindWalk trades on The Nasdaq Capital Market under the ticker symbol HYFT. Public disclosures identify MindWalk Holdings Corp. as a foreign issuer that files annual reports on Form 20-F and current reports on Form 6-K. The company has referenced principal executive offices in Victoria, British Columbia and Austin, Texas in its regulatory filings, reflecting its North American footprint.

Bio-Native AI platform and HYFT technology

According to multiple company press releases, MindWalk is powered by its patented HYFT® technology and the LensAI™ platform. HYFT patterns are described as evolution-shaped subsequence codes that link sequence, structure and function. MindWalk states that HYFT technology can work without sequence alignment and capture multi-dimensional functional fingerprints that encode geometry, stability and biophysical constraints. These patterns are used to reveal functional logic in biological systems, even when sequence variation obscures it.

The LensAI platform is presented as a software environment that harmonizes and analyzes diverse biological data. Company materials explain that LensAI links sequences, functions, experimental outcomes and scientific evidence into a continuously learning system. MindWalk emphasizes that LensAI is designed to provide explainability, biological traceability and full lineage tracking for AI-informed decisions in discovery and development.

Integration of in silico and wet lab capabilities

MindWalk describes its operating model as combining in silico and wet lab operations for biologics discovery and development. Public communications state that the company "closes the loop" with an integrated, full-stack wet lab. This integration is positioned as enabling the conversion of computational insights into validated biological assets.

Across its disclosures, MindWalk highlights several capabilities supported by its platform:

  • Rapid epitope mapping
  • De novo molecular design
  • In silico vaccine exploration
  • Population-scale biologics analytics

The company states that these capabilities are intended to help convert insight into validated candidates with speed and precision.

Therapeutic research focus and programs

MindWalk characterizes itself as a Bio-Native AI therapeutic research and technology company. Its public updates describe multiple AI-driven programs that are derived from its HYFT and LensAI platform.

In its influenza work, MindWalk reports that it has identified a breakthrough functional constraint that persists across influenza A and influenza B viruses despite continual evolution. Using HYFT Deep Data technology, the company states that it has detected a functional pattern embedded in influenza biology that remains intact beneath surface-level genetic change. MindWalk describes this as a biophysical requirement influenza must satisfy for infection, and reports that the same HYFT-defined pattern has been observed across human, avian and swine-associated influenza A datasets, as well as both major influenza B lineages.

MindWalk has also announced a universal influenza program that it intends to advance through additional pre-clinical validation and IND-enabling work within a dedicated portfolio structure. The company has indicated that, following sufficient pre-clinical de-risking, it plans to out-license this program or pursue development partnerships with global pharmaceutical companies.

In metabolic and aging biology, MindWalk has reported an AI-designed GLP-1 receptor agonist program. The company states that its GLP-1 peptides were designed entirely in silico using LensAI and that these sequences matched or exceeded semaglutide in receptor activation assays. Building on this work, MindWalk has described a first-in-class dual-pathway regimen in which its GLP-1 receptor agonists are co-administered with a proprietary companion therapeutic directed at a second, non-overlapping pathway linked to healthy aging and systemic resilience. The company notes that the specific target details of this companion therapeutic remain undisclosed while validation and protection activities proceed.

MindWalk has also discussed a universal dengue vaccine initiative. Using LensAI and HYFT patterns to analyze multi-omic data, the company reports that it pinpointed a highly conserved, discontinuous epitope shared across all four dengue virus serotypes. Public statements indicate that preclinical planning for this program is underway and that a collaborator has been selected to advance it.

Neurodegeneration and biologics discovery

In neurodegenerative disease, MindWalk has announced the discovery and validation of monoclonal antibodies and intrabodies that selectively target misfolded, pathogenic TDP-43, a protein implicated in amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and certain forms of Alzheimer’s disease. The company states that this work demonstrates its ability to discriminate with structural precision between toxic protein conformations and their healthy counterparts, and to anchor these findings in wet-lab validation.

MindWalk describes this TDP-43 work as resolving both structural and functional logic of neurodegeneration and converting that understanding into selective, evidence-linked biological assets. The company has noted that the study provides external validation of its platform capabilities in a client-driven setting and reinforces its position as a discovery partner for complex neurodegenerative programs.

Business model and partnerships

MindWalk’s disclosures indicate that it operates a proprietary Bio-Native AI platform and engages in project-based and platform-related revenue streams. The company reports that it partners with global pharmaceutical and biotechnology companies to support biologics discovery, de-risk drug development and generate AI-driven programs. It has also described an approach in which platform-derived programs are structured as standalone development portfolios, with assets and liabilities for each program ringfenced in segregated portfolios.

MindWalk has reported that it is forming a corporation in the Cayman Islands to house segregated portfolios for each AI-driven program. Under this structure, investors can participate directly in individual portfolios rather than only through the public company. The company has stated that this arrangement is intended to align capital, risk and decision-making with each individual asset while preserving the integrity of its core discovery platform.

Corporate evolution and identity

MindWalk Holdings Corp. has disclosed that it was formerly known as ImmunoPrecise Antibodies and that it completed a corporate rebranding to MindWalk. The company has indicated that this rebranding united ImmunoPrecise Antibodies, BioStrand and Talem under a single identity and that its Nasdaq ticker was changed to HYFT to reflect its HYFT technology.

In connection with its strategic focus, MindWalk has reported the sale of its Netherlands operations, classifying those operations as discontinued in its financial statements. The company has stated that the divestiture generated net proceeds that strengthened its balance sheet and allowed it to focus resources on Bio-Native AI initiatives and high-value wet lab programs aligned with LensAI.

Capital markets activity and governance

MindWalk’s SEC filings describe various capital markets and governance activities. The company has entered into a Sales Agreement with JonesTrading Institutional Services LLC to offer and sell common shares through an at-the-market equity offering facility under an effective shelf registration statement. It has also announced a share repurchase program authorizing the repurchase of up to a specified number of common shares over a defined period, subject to market conditions and regulatory requirements.

The company files current reports on Form 6-K that include earnings releases, pro forma financial information, statements of executive compensation and reports of voting results. These filings are incorporated by reference into MindWalk’s registration statements on Form F-3 and Form S-8, providing additional detail on its financial position, equity structure and compensation arrangements.

Position within biotechnology and healthcare

Within the broader biotechnology and healthcare sector, MindWalk presents itself as a Bio-Native AI and TechBio company focused on biologics, vaccines and therapeutics that are informed by its AI and Deep Data capabilities. Its public communications emphasize the use of AI-native data intelligence to identify functional constraints in pathogens, design biologics in silico and link computational insights to wet-lab validation.

According to its disclosures, MindWalk’s platform is applied across infectious disease, metabolic and aging biology, and neurodegeneration, among other areas. The company highlights that its approach is intended to support rational vaccine and therapeutic discovery, improve decision quality and reduce downstream failure in drug discovery programs.

Stock Performance

$0.9000
-0.74%
-0.0067
Last updated: at
-48.9%
Performance 1 year
$42.8M

MindWalk Holdings (HYFT) closed at $0.9000 on November 18, 2026. Over the past 12 months, the price has lost 48.9%.

See what a $1,000 investment in HYFT would be worth today

Average down calculator for HYFT

HYFT Metrics & Rankings

Price returns through November 18, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Financial Highlights

MindWalk Holdings generated $11.4M in revenue in FY2026, retaining a 58.8% gross margin, and net income was -$10.2M, reflecting a -89.7% net profit margin. Diluted earnings per share stood at -$0.23. The company generated -$9.2M in operating cash flow. The current ratio was 2.80, measuring current assets divided by current liabilities.

$11.4M
Revenue (FY2026)
-$10.2M
Net Income (FY2026)
-$9.2M
Operating Cash Flow

Upcoming Events

YEAR
2027
2027 Corporate

Next annual meeting

MindWalk's next annual meeting (date TBA) when directors' terms and auditor appointment expire; location/webcast to be announced.
NOV
16
November 16, 2029 Financial

Credit Facility Maturity

Maturity of MindWalk's US$30M revolving credit facility with Sanabil Cayman; matures 2029-11-16; 12-month extension available.

MindWalk Holdings has 2 upcoming scheduled events. The next event, "Next annual meeting", is expected in 2027. 1 of them is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the HYFT stock price.

Short Interest History

Last 12 Months

Short interest in MindWalk Holdings (HYFT) currently stands at 1.1 million shares, up 4.3% from the previous reporting period, representing 2.5% of the float. Since November 2025, short interest has increased by 118.3%.

Days to Cover History

Last 12 Months

Days to cover for MindWalk Holdings (HYFT) currently stands at 6.3 days, up 167.7% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has increased by 424.2%. Across the settlements charted above, it has ranged from 1.0 to 7.1 days.

HYFT Company Profile & Sector Positioning

MindWalk Holdings (HYFT) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing HYFT often look at related companies in the same sector, including Gain Therapeutics, Inc. (GANX), Oncolytics Biotech, Inc. (ONCY), MiNK Therapeutics, Inc. (INKT), Rein Therapeutics, Inc. (RNTX), and Impact BioMedical, Inc. (IBO). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate HYFT's relative position within its industry.

Frequently Asked Questions

The current stock price of MindWalk Holdings (HYFT) is $0.9000 as of November 18, 2026.

The market cap of MindWalk Holdings (HYFT) is approximately $42.8M. Learn more about what market capitalization means .

The FY2026 revenue of MindWalk Holdings (HYFT) is $11.4M, from its most recent completed fiscal year.

The FY2026 net income of MindWalk Holdings (HYFT) is -$10.2M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of MindWalk Holdings (HYFT) is -$0.23 for FY2026, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of MindWalk Holdings (HYFT) is -$9.2M for FY2026, its most recent completed fiscal year. Learn about cash flow.

The net profit margin of MindWalk Holdings (HYFT) is -89.7% for FY2026, its most recent completed fiscal year. Learn about profit margins.

The gross profit margin of MindWalk Holdings (HYFT) is 58.8% for FY2026, its most recent completed fiscal year. Learn about gross margins.

The current ratio of MindWalk Holdings (HYFT), current assets divided by current liabilities, was 2.80 at the end of FY2026, its most recent completed fiscal year. Learn about liquidity ratios.

The gross profit of MindWalk Holdings (HYFT) is $6.7M for FY2026, its most recent completed fiscal year.

MindWalk Holdings Corp. is a Bio-Native AI company in the biotechnology and healthcare sector that focuses on transforming drug discovery and development. According to its public disclosures, it integrates artificial intelligence, multi-omics data and advanced laboratory research to accelerate the discovery and development of biologics, vaccines and therapeutics.

MindWalk describes its patented HYFT technology as using evolution-shaped subsequence codes that link sequence, structure and function. Company materials state that HYFT can work without sequence alignment and capture multi-dimensional functional fingerprints that encode geometry, stability and biophysical constraints, helping reveal functional logic in biological systems even when sequence variation is present.

The LensAI platform is MindWalk’s software environment built on HYFT patterns. Public descriptions explain that LensAI harmonizes and analyzes diverse biological data, linking sequences, functions, experimental outcomes and scientific evidence into a continuously learning system. The company emphasizes that LensAI is designed to provide explainability, biological traceability and full lineage tracking for AI-informed decisions in discovery and development.

MindWalk has publicly discussed programs in several areas. These include a universal influenza program based on a functional constraint identified across influenza A and B, an AI-designed GLP-1 receptor agonist program with a proposed dual-pathway regimen related to aging biology, a universal dengue vaccine initiative built around a conserved discontinuous epitope, and neurodegenerative disease work targeting misfolded pathogenic TDP-43.

The company states that it combines in silico and wet lab operations for biologics discovery and development. MindWalk describes its model as unifying sequence, structure, function and literature into a single computational language through HYFT and LensAI, and then closing the loop with an integrated, full-stack wet lab to validate and refine biological assets derived from its computational insights.

MindWalk reports that it operates a proprietary Bio-Native AI platform and generates revenue from project-based and platform-related activities. It partners with pharmaceutical and biotechnology companies to support biologics discovery and de-risk drug development. The company has also described structuring platform-derived programs as standalone development portfolios with segregated assets and liabilities, allowing investors to participate directly in individual AI-driven programs.

Yes. MindWalk has disclosed that it was formerly known as ImmunoPrecise Antibodies and that it completed a corporate rebranding to MindWalk, uniting ImmunoPrecise Antibodies, BioStrand and Talem under one identity. The company also changed its Nasdaq ticker to HYFT and reported the sale of its Netherlands operations, which are now classified as discontinued operations in its financial statements.

MindWalk states in its press releases and SEC filings that its common shares trade on The Nasdaq Capital Market under the ticker symbol HYFT.

According to company descriptions, MindWalk’s platform supports rapid epitope mapping, de novo molecular design, in silico vaccine exploration and population-scale biologics analytics. These capabilities are presented as ways to convert biological insight into validated candidates with speed and precision.

MindWalk reports that it partners with global pharmaceutical and biotechnology companies to drive innovation, de-risk drug development and unlock new therapeutic possibilities. In neurodegeneration, for example, it has highlighted that its TDP-43 work provided external validation of its platform capabilities in a client-driven setting and reinforced its position as a discovery partner for complex programs.